The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Shifting landscape of resistance to next-generation ALK inhibitors with evolving treatment paradigm in ALK+ lung cancer.
 
Sarah Waliany
Consulting or Advisory Role - AstraZeneca
 
Andrew Do
No Relationships to Disclose
 
Jenn Peterson
No Relationships to Disclose
 
Joyce Liang
No Relationships to Disclose
 
Aaron Hata
Consulting or Advisory Role - Amgen; Engine Biosciences; Nuvalent, Inc.; Oncovalent Therapeutics; Pfizer; TigaTx; Tolremo
Research Funding - Amgen; Bridgebio; Bristol-Myers Squibb; C4 Therapeutics; Lilly; Novartis; Nuvalent, Inc.; Pfizer; Scorpion Therapeutics
 
Ibiayi Dagogo-Jack
Honoraria - American Lung Association; American Society of Clinical Oncology; Aptitude Health; Creative Educational Concepts; DAVA Oncology; Foundation Medicine; Medscape; OncLive; Peerview; Research to Practice; Total Health
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; BostonGene; Bristol-Myers Squibb; Catalyst Clinical Research; Genentech; Genzyme; Gilead Sciences; Janssen; Lilly; Merus; Novocure; Pfizer; Roche; Syros Pharmaceuticals; Thermo Fisher Scientific; Xcovery
Research Funding - Array BioPharma; Genentech; Guardant Health; Novartis; Pfizer
Travel, Accommodations, Expenses - Array BioPharma; Pfizer
 
Justin Gainor
Employment - Ironwood Pharmaceuticals (I)
Stock and Other Ownership Interests - AI proteins; Ironwood Pharmaceuticals (I)
Honoraria - Merck; Novartis; Pfizer; Takeda
Consulting or Advisory Role - AI proteins; Amgen; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; Genentech; Gilead Sciences; iTEOS Therapeutics; Jounce Therapeutics; Karyopharm Therapeutics; Loxo/Lilly; Mariana Therapeutics; Merck; Merus; Mirati Therapeutics; Moderna Therapeutics; Novartis; Novocure; Nuvalent, Inc.; Pfizer; Sanofi; Silverback Therapeutics; Takeda
Research Funding - Adaptimmune; Alexo Therapeutics; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; Genentech; Genentech; Jounce Therapeutics; Merck; Moderna Therapeutics; NextPoint Therapeutics; Novartis; Novartis; Palleon Pharmaceuticals
 
Jessica Lin
Honoraria - Curio Science; HMP Education; Medscape; OncLive; PeerView
Consulting or Advisory Role - Anheart Therapeutics; AstraZeneca; Bayer; Blueprint Medicines; Bristol Myers Squibb; CLaiM Therapeutics; Daiichi Sankyo/Astra Zeneca; Elevation Oncology; Ellipses Pharma; Genentech; Gilead Sciences; Hyku Biosciences; Janssen; Lilly; Merus; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Nuvation Bio; Pfizer; Regeneron; Roche/Genentech; Takeda; Turning Point Therapeutics; Yuhan
Research Funding - Bayer (Inst); Bristol Myers Squibb; Elevation Oncology (Inst); Linnaeus Therapeutics (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Roche (Inst); Sutro Biopharma; Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb; Merus; Pfizer; Takeda